Table 3.

Comparison of progression-free survival between sunitinib and interferon-alpha arms in patient subsets having relatively low (<median) or high (≥median) baseline levels of each soluble protein

Patient subseta	Median PFS (months)		HR (95 % CI)	Log-rank P
	Sunitinib	IFN-α
VEGF-A
<Median	13.7	7.8	0.148 (0.038–0.579)	0.0019
≥Median	10.9	3.9	0.451 (0.149–1.36)	0.150
VEGF-C
<Median	13.7	5.1	0.190 (0.059–0.617)	0.0022
≥Median	11.1	7.8	0.551 (0.156–1.94)	0.348
sVEGFR-3
<Median	21.7	5.4	0.122 (0.024–0.615)	0.0034
≥Median	10.9	3.9	0.406 (0.147–1.12)	0.0719
IL-8
<Median	21.7	7.8	0.247 (0.077–0.787)	0.0114
≥Median	13.7	2.6	0.403 (0.12–1.35)	0.131

CI confidence interval, HR hazard ratio, IL-8 interleukin-8, IFN-α interferon-alpha, PFS progression-free survival, VEGF-A vascular endothelial growth factor A, VEGF-C vascular endothelial growth factor C, sVEGFR-3 soluble vascular endothelial growth factor receptor 3

^aTotal N = 33 and N = 30 for each protein in the sunitinib and IFN-α arms, respectively, apart from IL-8, where total N = 31 and N = 29 in the sunitinib and IFN-α arms, respectively